LWB1 Stock Overview
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mesoblast Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.87 |
| 52 Week High | AU$8.68 |
| 52 Week Low | AU$1.86 |
| Beta | 2.59 |
| 1 Month Change | 0% |
| 3 Month Change | 0.54% |
| 1 Year Change | -69.24% |
| 3 Year Change | -87.10% |
| 5 Year Change | -80.02% |
| Change since IPO | -82.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| LWB1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -69.2% | -21.1% | -0.3% |
Return vs Industry: LWB1 underperformed the German Biotechs industry which returned -13.9% over the past year.
Return vs Market: LWB1 underperformed the German Market which returned 4.1% over the past year.
Price Volatility
| LWB1 volatility | |
|---|---|
| LWB1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LWB1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LWB1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 83 | Silviu Itescu | www.mesoblast.com |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Mesoblast Limited Fundamentals Summary
| LWB1 fundamental statistics | |
|---|---|
| Market cap | €598.87m |
| Earnings (TTM) | -€67.42m |
| Revenue (TTM) | €6.89m |
86.9x
P/S Ratio-8.9x
P/E RatioIs LWB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LWB1 income statement (TTM) | |
|---|---|
| Revenue | US$7.47m |
| Cost of Revenue | US$48.13m |
| Gross Profit | -US$40.66m |
| Other Expenses | US$32.40m |
| Earnings | -US$73.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.064 |
| Gross Margin | -544.50% |
| Net Profit Margin | -978.41% |
| Debt/Equity Ratio | 22.8% |
How did LWB1 perform over the long term?
See historical performance and comparison